Computer-aided prediction of QT-prolongation

SAR and QSAR in Environmental Research

Volumn 19, Issue 1-2, 2008, Pages 81-90

  Filz, O ^a   Lagunin, A ^a   Filimonov, D ^a   Poroikov, V ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

1 phosphatidylinositol 4 phospate inhibitors; Dimethylargininase inhibitors; hERG channels blockade; PASS; PharmaExpert; QT interval prolongation

Indexed keywords

FORECASTING;

1-PHOSPHATIDYLINOSITOL-4-PHOSPATE INHIBITOR; CARDIAC ARRHYTHMIA; COMPUTER-AIDED; DIMETHYLARGININASE INHIBITOR; HERG CHANNEL BLOCKADE; PASS; PHARMAEXPERT; PHOSPHATIDYLINOSITOL 4; QT INTERVAL PROLONGATION; QT PROLONGATION;

BIOACTIVITY;

EID: 40249086736     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629360701844183     Document Type: Article

References (53)

1. M. Sanguinetti and M. Tristani-Firouzi, hERG potassium channels and cardiac arrhythmia, Nature 440 (2006), pp. 463-469.
2. D. Thomas, C.A. Karle, and J. Kiehn, The cardiac hERG/IKP- potassium channel as pharmacological target: structure, function, regulation and clinical applications, Curr. Pharm. Des. 12 (2006), pp. 2271-2383.
3. A. Aptula and M. Cronin, Prediction of hERG K+ blocking potency: application of structural knowledge, SAR QSAR Environ. Res. 15 (2004), pp. 399-411.
4. A. Aronov, Predictive in silico modeling for hERG channel blockers, Drug. Discov. Today. 10 (2005), pp. 149-155.
5. C. Jamielson et al., Medicinal chemistry of hERG optimizations: highlights and hang-ups, J. Med. Chem. 49 (2006), pp. 5029-5046.
6. O. Roshe et al., A virtual screening method for prediction of the hERG potassium channel liability of compounds libraries, ChemBioChem. 3 (2002), pp. 455-459.
7. A. Cavalli et al., Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of hERG K(+) channel blockers, J. Med. Chem. 45 (2002), pp. 3844-3853.
8. G. Keseru, Prediction of hERG potassium channel affinity by traditional and hologram QSAR methods, Bioorg. Med. Chem. Lett. 13 (2003), pp. 2773-2775.
9. R. Pearlstein et al., Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior, J. Med. Chem. 46 (2003), pp. 2017-2022.
10. A. Aronov and B. Goldman, A model for identifying hERG K+ channel blockers, Bioorg. Med, Chem. 12 (2004), pp. 2307-2315.
11. W. Bains, A. Basman, and C. White, HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study, Progr. Biophys. Mol. Biol. 86 (2004), pp. 3153-3159.
12. D. Fernandez et al., Physicochemical features of the hERG channel drug binding site, J. Biol. Chem. 279 (2004), pp. 10120-10127.
13. L. Du et al., Characterization of binding site of close-state KCNQ1 potassium channel by homology modelling, molecular docking and pharmacophore identification, Biochem. Biophys. Res. Communs. 332 (2005), pp. 677-687.
14. F. Osterberg and J. Aqvist, Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods, FEBS Lett. 579 (2005), pp. 2939-2944.
15. S. Ekins et al., Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Summon mapping techniques, J. Med. Chem. 49 (2006), pp. 5059-5071.
16. A. Aronov, Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers, J. Med. Chem. 49 (2006), pp. 6917-6921.
17. M. Sierstad and D. Agrafiotis, A QSAR model of hERG binding using a large, diverse and internally consistent training set, Chem. Biol. Drug. Des. 67 (2006), pp. 284-296.
18. A. Coi et al., Prediction of hERG potassium channel affinity by CODESSA approach, Bioorg. Med. Chem. 14 (2006), pp. 3153-3159.
19. M. Gepp and M. Hutter, Determination of hERG channel blockers using a decision tree, Bioorg. Med. Chem. 14 (2006), pp. 5325-5332.
20. L. Lu et al., A novel structure-based virtual screening model for the hERG channel blockers, Biochem. Biophys. Res. Communs. 355 (2007), pp. 889-894.
21. D. Diller and D. Hobbs, Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation, J. Comput. Aid. Mol. Des. 21 (2007), pp. 379-393.
22. U. Norinder, In silico modelling of ADMET - A minireview of work from 2000 to 2004, SAR QSAR Environ. Res. 16 (2004), pp. 1-11.
23. C. Helma, In silico predictive toxicology: the state-of-the-art and strategies to predict human health effects, Curr. Opin. Drug Discov. Devel. 8 (2005), pp. 27-31.
24. S.E. O'Brien and M.J. De Groot, Greater than the sum of its parts: combining models for useful ADMET prediction, J. Med. Chem. 48 (2005), pp. 1287-1291.
25. M. Sangunietti and J. Mitcheson, Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 26 (2005), pp. 119-124.
26. A. Sadym et al., Prediction of biological activity spectra via the Internet, SAR QSAR Environ. Res. 14 (2003), pp. 339-347.
27. V. Poroikov et al., PASS: Identification of probable targets and mechanisms of toxicity, SAR QSAR Environ. Res. 18 (2007), pp. 101-110.
28. V. Poroikov and D. Filimonov, PASS: Prediction of Biological Activity Spectra for Substances, in Predictive Toxicology, C. Helma, ed., Taylor & Francis, Boca Raton, USA, 2005, pp. 459-478.
29. http://www.ibmc.msk.ru/PASS
30. V. Poroikov et al., Robustness of biological activity spectra predicting by computer program PASS for non-congeneric sets of chemical compounds, J. Chem. Inform. Comput. Sci. 40 (2000), pp. 1349-1355.
31. B. Anson et al., Blockade of HERG channels by HIV protease inhibitors, The Lancet. 365 (2005), pp. 682-686.
32. A. Fossa et al., Differential effect of HERG blocking agents on cardiac electrical alternons in the guinea pig, Eur. J. Pharmacol. 486 (2004), pp. 209-221.
33. B. Guth et al., Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization, J. Pharmacol Toxicol. Meth. 49 (2004), pp. 159-69.
34. Y. Hara and K. Kizaki, Antimalarial drugs inhibit the acetylcholine-receptor-operated potassium current in atrial myocytes, Heart Lung Circ. 11 (2002), pp. 112-116.
35. S. Kongsamut et al., A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs, Eur. J. Pharmacol. 450 (2002), pp. 37-41.
36. P. Milberg et al., Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of'LQT3, Cardiovasc. Res. 65 (2005), pp. 397-404.
37. I. Paakkari, Cardiotoxicity of new antihistamines and cisapride, Toxicol. Lett. 127 (2002), pp. 279-284.
38. S. Remich, M. Kilborn, and R. Woosley, The role of internet-based registries in tandem with genetic screening for the study of drug-induced arrythmias, Curr. Ther. Res. 62 (2001), pp. 787-795.
39. E. Vlaminckx et al., In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation, Eur. J. Pharmacol. 553 (2006), pp. 229-239.
40. D. Thomas et al., Inhibition of human ether-a-go-go-related gene potassium channels by alpha l-adrenoceptor antagonists prazosin, doxazosin, and terazosin, Naunyn Schmiedebergs Arch Pharmacol. 369 (2004), pp. 462-472.
41. D. Garg, T. Gandhi, and C Mohan, Exploring QTSR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques, J. Mol. Graph. Model. (2007). [Epub ahead of print].
42. A. Paul, H. Witchel, and J. Hancox, Inhibition of HERG potassium channel current by the class la antiarrhythmic agent disopyramide, Biochem. Biophys. Res. Commun, 280 (2001), pp. 1243-1250.
43. S. Rajamani et al., Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine, Br. J. Pharmacol, 149 (2006), pp. 481-489.
44. A. Lacerda, et al., Alfuzosin delays cardiac repolarization by a novel mechanism, J. Pharmacol. Exp. Ther. (2007). [Epub ahead of print].
45. http://www.mdl.com.
46. V. Poroikov, A. Lagunin, and D. Filimonov, Pharmaexpert: diseases, targets and ligands - three in one, QSAR and Molecular Modelling in Rational Design of Bioactive Molecules, E. Aki Sener and I. Yalcin, eds., CADD & D Society, Ankara, Turkey, 2005.
47. http://www.brenda-enzymes.info R. Maas, Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA), Vase. Med. 10 (2005), 49-57.
48. J. Berube, M. Chahine, and P. Daleau, Modulation of HERG potassium channel properties by external pH, Pflugers Arch. 438 (1999), pp. 419-422.
49. Y. Katayama, Nitric oxide: mysterious messenger, Dojindo Newsletter. 1 (1995), pp. 1-26.
50. M. Sauviat and N. Pages, Cardiotoxicity of lindane, a gamma isomer of hexachlorocyclohexane, J. Soc. Biol. 196 (2002), p. 339.
51. Z. Wei et al., Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A, Chinese Med. Journ, 115 (2002), pp. 668-676.
52. E. Corbett and M. Michalak, Calcium, a signaling molecule in the endoplasmic reticulum?, Trends. Biochem. Sci. 25 (2000), pp. 307-311.
53. I. Rodriguez et al., Drug-induced QTprolongation in women during the menstrual cycle, JAMA. 285 (2001), pp. 1322-1326.